Loading...
Market
What will be the impact of Pfizer's RSV vaccine Abrysvo on hospitalizations due to RSV in immunocompromised adults by December 31, 2025?
2
Resolution / Starting Odds
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%
CDC hospitalization data and major health studies
Story
Pfizer's RSV Vaccine Shows Strong Results in Immunocompromised Adults
Aug 12, 2024, 11:00 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a strong immune response in a late-stage study involving immunocompromised adults aged 18 and older. The study showed that a single dose of the vaccine produced robust antibodies against RSV-A and RSV-B, indicating potential benefits for adults at risk of severe RSV-related illness. The top-line results highlight the vaccine's efficacy in generating an immune response in this vulnerable population.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
